Curanex Pharmaceuticals Inc Common Stock (CURX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Curanex Pharmaceuticals Inc Common Stock (CURX) has a cash flow conversion efficiency ratio of -0.643x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.19 Million) by net assets ($14.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CURX net asset value for net asset value and shareholders' equity analysis.
Curanex Pharmaceuticals Inc Common Stock - Cash Flow Conversion Efficiency Trend (2022–2024)
This chart illustrates how Curanex Pharmaceuticals Inc Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Curanex Pharmaceuticals Inc Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Curanex Pharmaceuticals Inc Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
DarkIris Inc. Class A Ordinary Shares
NASDAQ:DKI
|
N/A |
|
EXCELLENCE S.A. ZY -10
F:8XY
|
0.086x |
|
NRB Industrial Bearings Limited
NSE:NIBL
|
-0.012x |
|
Star Fashion Culture Holdings Limited
NASDAQ:STFS
|
-0.479x |
|
LCC Infotech Limited
NSE:LCCINFOTEC
|
0.267x |
|
Daesang Holdings Co Ltd Pref
KO:084695
|
0.058x |
|
North Arrow Minerals Inc
V:NAR
|
-0.011x |
|
Aurora Energy Metals Ltd
AU:1AE
|
0.261x |
Annual Cash Flow Conversion Efficiency for Curanex Pharmaceuticals Inc Common Stock (2022–2024)
The table below shows the annual cash flow conversion efficiency of Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024. For the full company profile with market capitalisation and key ratios, see Curanex Pharmaceuticals Inc Common Stock stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $503.36K | $-555.58K | -1.104x | -55169.43% |
| 2023-12-31 | $60.09K | $-120.00 | -0.002x | -100.61% |
| 2022-12-31 | $10.23K | $3.34K | 0.326x | -- |
About Curanex Pharmaceuticals Inc Common Stock
Curanex Pharmaceuticals Inc, a developmental stage pharmaceutical company, discovers, develops, and commercializes botanical drugs to treat patients suffering from inflammatory diseases. It develops Phyto-N for various therapeutic areas, including ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The company was formerly known as Fordman Pharma… Read more